Seres Therapeutics
Cambridge, Massachusetts, United States · Biotechnology, Health Care, Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres’ lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercializ
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 107
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Public (MCRB)
- Website
- serestherapeutics.com
- Company page
Recent activity at Seres Therapeutics
- : Marella Thorell Resigns as EVP and CFO of Seres Therapeutics
- : SEC 8-K (5.02):
- : SEC 8-K (1.01): On July 31, 2026, Seres Therapeutics, Inc. entered into a Termination Agreement with BMR-Sidney Research Campus LLC to early terminate a lease agreement, which will significantly reduce the Company's annual facilities costs and eliminate primary restoration obligations. The lease, originally dated November 11, 2015, allowed for the use of approximately 68,636 rentable square feet, of which 21,295 square feet will be surrendered effective August 1, 2026. As part of the termination, the Company will increase its letter of credit to $3.6 million, make a deferred payment of $3.85 million by January 4, 2027, and issue approximately $0.5 million in common stock to the Landlord. The termination will also revise the expiration date of the lease for the remaining space to December 31, 2026, from January 13, 2031, reflecting a strategic move to optimize costs.
- : SEC 8-K (5.02): On July 8, 2026, Seres Therapeutics, Inc. reported the departure of certain officers and the election of new directors during its reconvened 2026 Annual Meeting of Stockholders. The meeting, which had previously been adjourned due to a lack of quorum, saw stockholders approve an amendment to the 2025 Incentive Award Plan to increase the shares available for issuance by 900,000 shares. Additionally, three Class II directors were elected, including Stephen A. Berenson, Claire M. Fraser, Ph.D., and Richard N. Kender, to serve until the 2029 Annual Meeting. This amendment and the election were pivotal for the company’s strategic direction and compensation structure.
- : SEC 8-K (8.01): On July 8, 2026, the Company announced top-line results from a clinical study evaluating SER-155 in patients suffering from immune-related enterocolitis (irEC). The study involved 15 patients and was conducted at MSK under the direction of Dr. David Faleck. Participants exhibited clinically meaningful improvements, with 80% showing a response without the need for immunosuppressive therapy by Day 15. The results underscore the potential of SER-155 as a treatment to mitigate the severe gastrointestinal effects associated with immune checkpoint inhibitors, thereby addressing a critical unmet need in cancer therapy. The study indicates promising avenues for further development of this therapeutic approach, which could enhance treatment options for patients undergoing ICI therapy.
- : SEC 8-K (1.01): On June 2, 2026, Seres Therapeutics, Inc. entered into Amendment No. 1 (the 'APA Amendment') to the Asset Purchase Agreement with Société des Produits Nestlé S.A. The amendment terminates SPN’s obligations regarding the Second and Third Sales Milestone Payments and eliminates the Milestone Interest Payments. In exchange, SPN will make a one-time payment of $25.0 million to Seres, payable in two installments of $12.5 million on July 1, 2026, and October 1, 2026. This agreement reflects strategic changes in financial arrangements between the two companies concerning milestone payments based on product sales thresholds.
- : SEC 8-K (5.02): On May 30, 2026, Hans-Juergen Woerle, M.D., Ph.D. resigned from his position as a member of the board of directors of Seres Therapeutics, Inc., effective May 31, 2026. His departure is noted to be without any disagreement with the Company regarding its operations, policies, or practices. This change in the board composition could have strategic implications for the Company as it navigates its future directions and governance structure.
- : SEC 8-K (8.01):
- : SEC 8-K (7.01): On March 12, 2026, Seres Therapeutics, Inc. made a Regulation FD disclosure by posting an updated corporate presentation on its website, which can be found in the 'Investors and News' section. This presentation includes key updates pertinent to investors and is indicative of the company's strategic direction. The updated presentation, dated March 2026, aims to enhance transparency and provide shareholders with valuable insights. It is important to note that this information is not considered 'filed' under the Securities Exchange Act, thereby influencing its legal context but still serves a significant purpose for communication with current and potential investors.
- : Seres Therapeutics Appoints New Executive Leadership
Leadership
- Matthew, President & Chief Scientific Officer
- Marella Thorell, Executive Vice President
- Matthew Henn, Ph.D., President
- Richard N. Kender, Chief Executive Officer
- Marella Thorell, Chief Financial Officer
Verified email and direct lines for Seres Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Seres Therapeutics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Seres Therapeutics in the news
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance (Sep 08, 2026)
- Seres Therapeutics Stockholders Approve Sale of VOWST to Nestlé Health Science - citybiz (Sep 26, 2024)
- Nestlé Health Science Buys Vowst - Contagion Live (Jun 10, 2024)
- Microbiome Therapeutics Market Companies, Size & Trends 2026-2035 - Precedence Research (Oct 01, 2025)
- Seres Therapeutics Reveals Q1 2025 Results: Live Biotherapeutics Pioneer Updates Growth Strategy - Stock Titan (Apr 23, 2025)
- Seres Therapeutics and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™, the First and Only FDA-Approved Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection - Business Wire (Jun 05, 2023)
- Reducing Recurrent Clostridioides difficile Infection Risk With Oral Microbiome Therapy - Gastroenterology Advisor (May 15, 2024)
- India Antibiotic Resistance Market Size & Outlook, 2023-2030 - Grand View Research (Sep 10, 2024)
Companies similar to Seres Therapeutics
- Verastem Oncology · Biotechnology, Health Care, Therapeutics
- Precision BioSciences · Biotechnology, Health Care, Therapeutics
- Nimbus Therapeutics · Biotechnology, Health Care, Therapeutics
- Neurogene · Biotechnology, Health Care, Therapeutics
- Aura Biosciences, Inc. · Biotechnology, Health Care, Therapeutics
About Seres Therapeutics: questions and answers
What does Seres Therapeutics do?
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Seres’ lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiome therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercializ
Where is Seres Therapeutics headquartered?
Seres Therapeutics is headquartered in Cambridge, Massachusetts, United States.
How many employees does Seres Therapeutics have?
Seres Therapeutics has about 107 employees.
Who leads Seres Therapeutics?
Matthew is a President & Chief Scientific Officer at Seres Therapeutics.
What is the latest news on Seres Therapeutics?
On Oct 26, 2026, Marella Thorell Resigns as EVP and CFO of Seres Therapeutics
Is Seres Therapeutics a public company?
Yes. Seres Therapeutics is publicly traded under the ticker MCRB.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy